{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T20:26:10Z","timestamp":1787430370197,"version":"build-2736575974"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12325-026-03609-0","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T09:25:22Z","timestamp":1780737922000},"page":"3965-3978","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Real-World Target Trial Emulation of Eteplirsen, Casimersen, and Golodirsen to Evaluate Survival Among Patients with Duchenne Muscular Dystrophy"],"prefix":"10.1007","volume":"43","author":[{"given":"Sai","family":"Dharmarajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3474-6874","authenticated-orcid":false,"given":"Shannon","family":"Grabich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0712-1135","authenticated-orcid":false,"given":"Richard","family":"Baxter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aalok","family":"Nadkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Schermer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"3609_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01430-8","volume":"15","author":"S Crisafulli","year":"2020","unstructured":"Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifir\u00f2 G. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J Rare Dis. 2020;15:141.","journal-title":"Orphanet J Rare Dis"},{"key":"3609_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00248-3","volume":"7","author":"D Duan","year":"2021","unstructured":"Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021;7:13.","journal-title":"Nat Rev Dis Primers"},{"key":"3609_CR3","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1212\/WNL.0b013e318225ab2e","volume":"77","author":"E Mazzone","year":"2011","unstructured":"Mazzone E, Vasco G, Sormani M, et al. Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology. 2011;77:250\u20136.","journal-title":"Neurology"},{"key":"3609_CR4","first-page":"117","volume":"31","author":"S Rall","year":"2012","unstructured":"Rall S, Grimm T. Survival in Duchenne muscular dystrophy. Acta Myol. 2012;31:117.","journal-title":"Acta Myol"},{"key":"3609_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01862-w","volume":"16","author":"SM Szabo","year":"2021","unstructured":"Szabo SM, Salhany RM, Deighton A, Harwood M, Mah J, Gooch KL. The clinical course of Duchenne muscular dystrophy in the corticosteroid treatment era: a systematic literature review. Orphanet J Rare Dis. 2021;16:237.","journal-title":"Orphanet J Rare Dis"},{"key":"3609_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.3331","volume":"13","author":"J Broomfield","year":"2023","unstructured":"Broomfield J, Abrams K, Latimer N, Guglieri M, Rutherford M, Crowther M. Natural history of Duchenne muscular dystrophy in the United Kingdom: a descriptive study using the Clinical Practice Research Datalink. Brain Behav. 2023;13:e3331.","journal-title":"Brain Behav"},{"key":"3609_CR7","doi-asserted-by":"publisher","first-page":"1701418","DOI":"10.1183\/13993003.01418-2017","volume":"51","author":"A LoMauro","year":"2018","unstructured":"LoMauro A, Romei M, Gandossini S, et al. Evolution of respiratory function in Duchenne muscular dystrophy from childhood to adulthood. Eur Respir J. 2018;51:1701418.","journal-title":"Eur Respir J"},{"key":"3609_CR8","doi-asserted-by":"publisher","first-page":"e2304","DOI":"10.1212\/WNL.0000000000012910","volume":"97","author":"J Broomfield","year":"2021","unstructured":"Broomfield J. Life expectancy in Duchenne muscular dystrophy: reproduced individual patient data meta-analysis. Neurology. 2021;97:e2304\u201314.","journal-title":"Neurology"},{"key":"3609_CR9","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.nmd.2022.04.008","volume":"32","author":"P Paramsothy","year":"2022","unstructured":"Paramsothy P, Wang Y, Cai B, et al. Selected clinical and demographic factors and all-cause mortality among individuals with Duchenne muscular dystrophy in the Muscular Dystrophy Surveillance, Tracking, and Research Network. Neuromuscul Disord. 2022;32:468\u201376.","journal-title":"Neuromuscul Disord"},{"key":"3609_CR10","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s10654-021-00819-4","volume":"37","author":"L Wahlgren","year":"2022","unstructured":"Wahlgren L, Kroksmark AK, Tulinius M, Sofou K. One in five patients with Duchenne muscular dystrophy dies from other causes than cardiac or respiratory failure. Eur J Epidemiol. 2022;37:147\u201356.","journal-title":"Eur J Epidemiol"},{"key":"3609_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3233\/JND-200556","volume":"8","author":"M Quattrocelli","year":"2021","unstructured":"Quattrocelli M, Zelikovich AS, Salamone IM, Fischer JA, McNally EM. Mechanisms and clinical applications of glucocorticoid steroids in muscular dystrophy. J Neuromuscul Dis. 2021;8:39\u201352.","journal-title":"J Neuromuscul Dis"},{"key":"3609_CR12","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jacc.2012.12.008","volume":"61","author":"G Schram","year":"2013","unstructured":"Schram G, Fournier A, Leduc H, et al. All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy. J Am Coll Cardiol. 2013;61:948\u201354.","journal-title":"J Am Coll Cardiol"},{"key":"3609_CR13","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1177\/0883073810371004","volume":"25","author":"RT Moxley 3rd","year":"2010","unstructured":"Moxley RT 3rd, Pandya S, Ciafaloni E, Fox DJ, Campbell K. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol. 2010;25:1116\u201329.","journal-title":"J Child Neurol"},{"key":"3609_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1398050","volume":"15","author":"A Hurley-Novatny","year":"2024","unstructured":"Hurley-Novatny A, Chang D, Murakami K, Wang L, Li H. Poor bone health in Duchenne muscular dystrophy: a multifactorial problem beyond corticosteroids and loss of ambulation. Front Endocrinol. 2024;15:1398050.","journal-title":"Front Endocrinol"},{"key":"3609_CR15","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/ana.23982","volume":"74","author":"JR Mendell","year":"2013","unstructured":"Mendell JR, Rodino-Klapac LR, Sahenk Z, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol. 2013;74:637\u201347.","journal-title":"Ann Neurol"},{"key":"3609_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015858","volume":"98","author":"LN Alfano","year":"2019","unstructured":"Alfano LN, Charleston JS, Connolly AM, et al. Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy. Medicine (Baltimore). 2019;98:e15858.","journal-title":"Medicine (Baltimore)"},{"key":"3609_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12040912","volume":"12","author":"M Assefa","year":"2024","unstructured":"Assefa M, Gepfert A, Zaheer M, Hum JM, Skinner BW. Casimersen (AMONDYS 45\u2122): an antisense oligonucleotide for Duchenne muscular dystrophy. Biomedicines. 2024;12:912.","journal-title":"Biomedicines"},{"key":"3609_CR18","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3233\/JND-210643","volume":"8","author":"CM McDonald","year":"2021","unstructured":"McDonald CM, Shieh PB, Abdel-Hamid HZ, et al. Open-label evaluation of eteplirsen in patients with Duchenne muscular dystrophy amenable to exon 51 skipping: PROMOVI trial. J Neuromuscul Dis. 2021;8:989\u20131001.","journal-title":"J Neuromuscul Dis"},{"key":"3609_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1089\/nat.2021.0043","volume":"32","author":"L Servais","year":"2022","unstructured":"Servais L, Mercuri E, Straub V, et al. Long-term safety and efficacy data of golodirsen in ambulatory patients with Duchenne muscular dystrophy amenable to exon 53 skipping: a first-in-human, multicenter, two-part, open-label, phase\u00a01\/2 trial. Nucleic Acid Ther. 2022;32:29\u201339.","journal-title":"Nucleic Acid Ther"},{"key":"3609_CR20","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3233\/JND-221656","volume":"10","author":"PR Clemens","year":"2023","unstructured":"Clemens PR, Rao VK, Connolly AM, et al. Efficacy and safety of viltolarsen in boys with Duchenne muscular dystrophy: results from the phase\u00a02, open-label, 4-year extension study. J Neuromuscul Dis. 2023;10:439\u201347.","journal-title":"J Neuromuscul Dis"},{"key":"3609_CR21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/mus.27347","volume":"64","author":"KR Wagner","year":"2021","unstructured":"Wagner KR, Kuntz NL, Koenig E, et al. Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: a randomized, double-blind, placebo-controlled, dose-titration trial. Muscle Nerve. 2021;64:285\u201392.","journal-title":"Muscle Nerve"},{"key":"3609_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3233\/JND-210665","volume":"9","author":"O Mitelman","year":"2022","unstructured":"Mitelman O, Abdel-Hamid HZ, Byrne BJ, et al. A combined prospective and retrospective comparison of long-term functional outcomes suggests delayed loss of ambulation and pulmonary decline with long-term eteplirsen treatment. J Neuromuscul Dis. 2022;9:39\u201352.","journal-title":"J Neuromuscul Dis"},{"key":"3609_CR23","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1177\/22143602251366721","volume":"13","author":"J Iff","year":"2025","unstructured":"Iff J, Desguerre I, Liu Y, et al. Association between exon-skipping therapy with eteplirsen and cardiac outcomes in Duchenne muscular dystrophy. J Neuromuscul Dis. 2025;13:179\u201389.","journal-title":"J Neuromuscul Dis"},{"key":"3609_CR24","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1177\/1932296819832653","volume":"14","author":"DC Klonoff","year":"2020","unstructured":"Klonoff DC. The expanding role of real-world evidence trials in health care decision making. J Diabetes Sci Technol. 2020;14:174\u20139.","journal-title":"J Diabetes Sci Technol"},{"key":"3609_CR25","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1002\/jcph.2134","volume":"62","author":"J Liu","year":"2022","unstructured":"Liu J, Barrett JS, Leonardi ET, et al. Natural history and real-world data in rare diseases: applications, limitations, and future perspectives. J Clin Pharmacol. 2022;62:S38-55.","journal-title":"J Clin Pharmacol"},{"key":"3609_CR26","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1055\/a-1910-4154","volume":"13","author":"EV Bernstam","year":"2022","unstructured":"Bernstam EV, Applegate RJ, Yu A, et al. Real-world matching performance of deidentified record-linking tokens. Appl Clin Inform. 2022;13:865\u201373.","journal-title":"Appl Clin Inform"},{"key":"3609_CR27","unstructured":"Datavant. Datavant Connect: Tokenization software for health data. Phoenix, AZ; 2023. https:\/\/www.datavant.com\/white-papers\/datavant-connect-overview-tokenization-technology-structured-data. Accessed 01 May 2025."},{"key":"3609_CR28","unstructured":"Grabich D, Nadkar, Dharmarajan. Validation of a claims algorithm for identifying patients with Duchenne muscular dystrophy in US administrative claims with genetic laboratory data. Poster presented at: International Society for Pharmacoepidemiology Annual Meeting (ISPE); August 22\u201326, 2025; Washington, DC, USA. Poster C-201."},{"key":"3609_CR29","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12916-021-02151-w","volume":"19","author":"VT Nguyen","year":"2021","unstructured":"Nguyen VT, Engleton M, Davison M, Ravaud P, Porcher R, Boutron I. Risk of bias in observational studies using routinely collected data of comparative effectiveness research: a meta-research study. BMC Med. 2021;19:279.","journal-title":"BMC Med"},{"key":"3609_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/EDE.0000000000001808","volume":"36","author":"MA Hern\u00e1n","year":"2025","unstructured":"Hern\u00e1n MA, Sterne JA, Higgins JP, Shrier I, Hern\u00e1ndez-D\u00edaz S. A structural description of biases that generate immortal time. Epidemiology. 2025;36:107\u201314.","journal-title":"Epidemiology"},{"key":"3609_CR31","doi-asserted-by":"publisher","first-page":"e087179","DOI":"10.1136\/bmj-2025-087179","volume":"390","author":"AG Cashin","year":"2025","unstructured":"Cashin AG, Hansford HJ, Hern\u00e1n MA, et al. Transparent reporting of observational studies emulating a target trial: the TARGET statement. BMJ. 2025;390:e087179.","journal-title":"BMJ"},{"key":"3609_CR32","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12874-023-02000-9","volume":"23","author":"G Scola","year":"2023","unstructured":"Scola G, Chis Ster A, Bean D, Pareek N, Emsley R, Landau S. Implementation of the trial emulation approach in medical research: a scoping review. BMC Med Res Methodol. 2023;23:186.","journal-title":"BMC Med Res Methodol"},{"key":"3609_CR33","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1093\/aje\/kwae471","volume":"194","author":"L Benz","year":"2025","unstructured":"Benz L, Mukherjee R, Wang R, et al. Adjusting for selection bias due to missing eligibility criteria in emulated target trials. Am J Epidemiol. 2025;194:3126\u201339.","journal-title":"Am J Epidemiol"},{"key":"3609_CR34","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/mus.28075","volume":"70","author":"J Iff","year":"2024","unstructured":"Iff J, Done N, Tuttle E, et al. Survival among patients receiving eteplirsen for up to 8\u00a0years for the treatment of Duchenne muscular dystrophy and contextualization with natural history controls. Muscle Nerve. 2024;70:60\u201370.","journal-title":"Muscle Nerve"},{"key":"3609_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1098454","volume":"14","author":"A Videnovic","year":"2023","unstructured":"Videnovic A, Pfeiffer H, Tylki-Szyma\u0144ska A, Berry-Kravis E, Ezg\u00fc F, Ganju J. Study design challenges and strategies in clinical trials for rare diseases: lessons learned from pantothenate kinase-associated neurodegeneration. Front Neurol. 2023;14:1098454.","journal-title":"Front Neurol"},{"key":"3609_CR36","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183:758\u201364.","journal-title":"Am J Epidemiol"},{"key":"3609_CR37","doi-asserted-by":"publisher","first-page":"402","DOI":"10.7326\/ANNALS-24-01871","volume":"178","author":"MA Hern\u00e1n","year":"2025","unstructured":"Hern\u00e1n MA, Dahabreh IJ, Dickerman BA, Swanson SA. The target trial framework for causal inference from observational data: why and when is it helpful? Ann Intern Med. 2025;178:402\u20137.","journal-title":"Ann Intern Med"},{"key":"3609_CR38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.36469\/jheor.2023.87538","volume":"10","author":"O Baser","year":"2023","unstructured":"Baser O, Samayoa G, Yapar N, Baser E, Mete F. Use of open claims vs closed claims in health outcomes research. J Health Econ Outcomes Res. 2023;10:44\u201352.","journal-title":"J Health Econ Outcomes Res"},{"key":"3609_CR39","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/cge.12048","volume":"84","author":"E Viggiano","year":"2013","unstructured":"Viggiano E, Picillo E, Cirillo A, Politano L. Comparison of X-chromosome inactivation in Duchenne muscle\/myocardium-manifesting carriers, non-manifesting carriers and related daughters. Clin Genet. 2013;84:265\u201370.","journal-title":"Clin Genet"},{"key":"3609_CR40","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00439-016-1666-6","volume":"135","author":"E Viggiano","year":"2016","unstructured":"Viggiano E, Ergoli M, Picillo E, Politano L. Determining the role of skewed X-chromosome inactivation in developing muscle symptoms in carriers of Duchenne muscular dystrophy. Hum Genet. 2016;135:685\u201398.","journal-title":"Hum Genet"},{"key":"3609_CR41","unstructured":"US Food and Drug Administration. VILTEPSO (viltolarsen) prescribing information. 2021. Updated Mar 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212154s002lbl.pdf. Accessed 13 Mar 2026."},{"key":"3609_CR42","unstructured":"US Food and Drug Administration. VYONDYS 53 (golodirsen) prescribing information. 2024. Updated Jun 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/211970s010s011lbl.pdf. Accessed 13 Mar 2026."},{"key":"3609_CR43","unstructured":"US Food and Drug Administration. EXONDYS 51 (eteplirsen) prescribing information. 2025. Updated Aug 2025. https:\/\/www.exondys51.com\/pi. Accessed 13 Mar 2026."},{"key":"3609_CR44","unstructured":"US Food and Drug Administration. AMONDYS 45 (casimersen) prescribing information. 2026. Updated Jan 2026. https:\/\/www.amondys45.com\/pi. Accessed 13 Mar 2026."},{"key":"3609_CR45","unstructured":"Datavant, Veritas Data Research. Fact of Death mortality index. Phoenix, AZ; 2023. https:\/\/www.datavant.com\/white-papers\/mortality-data-in-healthcare-analytics. Accessed 01 May 2025."},{"key":"3609_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0265879","volume":"17","author":"N Ferizovic","year":"2022","unstructured":"Ferizovic N, Summers J, de Z\u00e1rate IBO, et al. Prognostic indicators of disease progression in Duchenne muscular dystrophy: a literature review and evidence synthesis. PLoS ONE. 2022;17:e0265879.","journal-title":"PLoS ONE"},{"key":"3609_CR47","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.032960","volume":"13","author":"JR Starnes","year":"2024","unstructured":"Starnes JR, Xu M, George-Durrett K, et al. Rate of change in cardiac magnetic resonance imaging measures is associated with death in Duchenne muscular dystrophy. J Am Heart Assoc. 2024;13:e032960.","journal-title":"J Am Heart Assoc"},{"key":"3609_CR48","doi-asserted-by":"publisher","DOI":"10.1148\/rg.240110","volume":"45","author":"D Toussie","year":"2025","unstructured":"Toussie D, Azour L, Garrana S, et al. Pulmonary calcification and ossification: pathogenesis, CT appearance, and specific disorders. Radiographics. 2025;45:e240110.","journal-title":"Radiographics"},{"key":"3609_CR49","doi-asserted-by":"publisher","first-page":"4300","DOI":"10.1007\/s00415-024-12372-7","volume":"271","author":"L Wahlgren","year":"2024","unstructured":"Wahlgren L, Kroksmark A-K, Lindblad A, Tulinius M, Sofou K. Respiratory comorbidities and treatments in Duchenne muscular dystrophy: impact on life expectancy and causes of death. J Neurol. 2024;271:4300\u20139.","journal-title":"J Neurol"},{"key":"3609_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26146742","volume":"26","author":"C Montagna","year":"2025","unstructured":"Montagna C, Maiani E, Pieroni L, Consalvi S. Duchenne muscular dystrophy: integrating current clinical practice with future therapeutic and diagnostic horizons. Int J Mol Sci. 2025;26:6742.","journal-title":"Int J Mol Sci"},{"key":"3609_CR51","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2025-0037","volume":"14","author":"S Grabich","year":"2025","unstructured":"Grabich S, Ung B, Nadkar A, DeYoung K, Signorovitch J, Veerapandiyan A. Real-world phosphorodiamidate morpholino oligomer treatment patterns in Duchenne muscular dystrophy: a claims-based analysis. J Comp Eff Res. 2025;14:e250037.","journal-title":"J Comp Eff Res"},{"key":"3609_CR52","doi-asserted-by":"crossref","unstructured":"Tian C, Grabich S, Veerapandiyan A, et al. Advancements from the EVOLVE study for assessing real-world experience with eteplirsen, golodirsen, and casimersen for the treatment of DMD. J Comp Eff Res. 2026;15:e250108.","DOI":"10.57264\/cer-2025-0108"},{"key":"3609_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0218683","volume":"14","author":"C Brogna","year":"2019","unstructured":"Brogna C, Coratti G, Pane M, et al. Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53. PLoS ONE. 2019;14:e0218683.","journal-title":"PLoS ONE"},{"key":"3609_CR54","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00246-021-02797-6","volume":"43","author":"KE Gambetta","year":"2022","unstructured":"Gambetta KE, McCulloch MA, Lal AK, et al. Diversity of dystrophin gene mutations and disease progression in a contemporary cohort of Duchenne muscular dystrophy. Pediatr Cardiol. 2022;43:855\u201367.","journal-title":"Pediatr Cardiol"},{"key":"3609_CR55","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3233\/JND-150100","volume":"2","author":"L Servais","year":"2015","unstructured":"Servais L, Montus M, Guiner CL, et al. Non-ambulant Duchenne patients theoretically treatable by exon 53 skipping have severe phenotype. J Neuromuscul Dis. 2015;2:269\u201379.","journal-title":"J Neuromuscul Dis"},{"key":"3609_CR56","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/mus.27463","volume":"65","author":"SM Szabo","year":"2022","unstructured":"Szabo SM, Gooch KL, Mickle AT, Salhany RM, Connolly AM. The impact of genotype on outcomes in individuals with Duchenne muscular dystrophy: a systematic review. Muscle Nerve. 2022;65:266\u201377.","journal-title":"Muscle Nerve"},{"key":"3609_CR57","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/mus.27427","volume":"65","author":"F Trucco","year":"2022","unstructured":"Trucco F, Ridout D, Domingos J, et al. Genotype-related respiratory progression in Duchenne muscular dystrophy\u2014a multicenter international study. Muscle Nerve. 2022;65:67\u201374.","journal-title":"Muscle Nerve"},{"key":"3609_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1304-8","volume":"19","author":"L Cowen","year":"2019","unstructured":"Cowen L, Mancini M, Martin A, Lucas A, Donovan JM. Variability and trends in corticosteroid use by male United States participants with Duchenne muscular dystrophy in the Duchenne Registry. BMC Neurol. 2019;19:84.","journal-title":"BMC Neurol"},{"key":"3609_CR59","unstructured":"Thada PK, Bhandari J, Forshaw KC, Umapathi KK. Becker muscular dystrophy. StatPearls [Internet]. Treasure Island: StatPearls Publishing; 2024."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03609-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03609-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03609-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T20:01:46Z","timestamp":1787428906000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03609-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":59,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3609"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03609-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}